Currently pregnant or breastfeeding-Neither Page 4 Posts on Medivizor
Navigation Menu

Currently pregnant or breastfeeding-Neither Posts on Medivizor

Searching for patients with Hodgkin lymphoma to try a new combination treatment

Posted by on Feb 25, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of Hodgkin lymphoma (HL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they specifically...

Read More

Searching for patients with chronic lymphocytic leukemia to test zanubrutinib compared to ibrutinib

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is looking at the effectiveness of zanubrutinib compared to ibrutinib in the treatment of patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). The main outcome to be measured will be overall response rate. The study will be carried out in the United States.  The details Chronic...

Read More

Searching for patients to test venetoclax with azacitidine treatment for acute myeloid leukemia

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is comparing the safety and effectiveness of venetoclax (Venclexta) and azacitidine (Vidaza) with azacitidine alone in patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. Complete remission (no signs of cancer after treatment) will also be measured. The details Acute...

Read More

Searching for patients with relapsed or refractory non-Hodgkin lymphoma to try a new drug

Posted by on Dec 3, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is evaluating the safety and effectiveness of a new drug called lisocabtagene maraleucel compared to standard chemotherapy for relapsed (recurrent) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be time to any disease-related complication. The...

Read More

Does radiotherapy improve outcomes for patients with primary breast diffuse large B-cell lymphoma?

Posted by on Jul 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...

Read More

Searching for patients with HER2 positive metastatic breast cancer to test palbociclib in combination with standard therapy.

Posted by on Oct 30, 2017 in Breast cancer | 0 comments

In a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States.  The details...

Read More

Looking for patients with relapsed follicular, marginal zone, or mantle cell lymphoma to test the effectiveness of a rituximab and lenalidomide maintenance therapy

Posted by on Sep 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....

Read More

Looking for patients with relapsed or refractory B-cell lymphoma to test the effectiveness of radioimmunotherapy followed by chemotherapy before stem cell transplant

Posted by on Sep 11, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of yttrium-90 (Y-90)-ibritumomab tiuxetan (Zevalin) followed by fludarabine (Fludara), total body irradiation, and donor peripheral blood stem cell transplant (PBSCT) in patients with relapsed or refractory (did not respond to treatment) B-cell lymphoma. The primary...

Read More

Searching for newly diagnosed patients with B-lineage acute lymphoblastic leukemia to participate in a randomized immunotherapy trial

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 3 clinical trial will test the effectiveness of blinatumomab (Blincyto) with chemotherapy versus chemotherapy alone in treating patients with newly diagnosed B lineage acute lymphoblastic leukemia (ALL) that is BCR-ABL negative. The primary outcome will be measured by the overall survival. The details Blinatumomab is...

Read More

Searching for patients with relapsed or refractory acute myeloid leukemia to test an immunotherapy

Posted by on Sep 11, 2017 in Leukemia | 0 comments

In a nutshell This phase 1 clinical trial will test the safety and effectiveness of AMV564 in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by adverse (negative) side effects and remission rate. The study is being conducted in Saint Louis, Missouri, New York City, and...

Read More

Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment

Posted by on Sep 3, 2017 in Leukemia | 0 comments

In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...

Read More

Looking for patients to test CAR T-cells in treating relapsed or refractory indolent non-Hodgkin lymphoma

Posted by on Aug 29, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate.   The details Axicabtagene ciloleucel is a chimeric antigen...

Read More